Lorecivivint
- Generic Name
- Lorecivivint
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H24FN7O
- CAS Number
- 1467093-03-3
- Unique Ingredient Identifier
- 42EK42WHI5
- Background
Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)
- First Posted Date
- 2022-11-03
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 496
- Registration Number
- NCT05603754
- Locations
- ๐บ๐ธ
Eastern Research, Inc., Hialeah, Florida, United States
๐บ๐ธTecTum Research, Hollywood, Florida, United States
๐บ๐ธConquest Research, LLC, Winter Park, Florida, United States
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04931667
- Locations
- ๐บ๐ธ
Research Site, Dallas, Texas, United States
A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 276
- Registration Number
- NCT04520607
- Locations
- ๐บ๐ธ
Research Site, Charlottesville, Virginia, United States
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT04385303
- Locations
- ๐บ๐ธ
Research Site, Richmond, Virginia, United States
๐บ๐ธResearch Site 1, Saint Louis, Missouri, United States
๐บ๐ธResearch Site 2, Saint Louis, Missouri, United States
A Study Utilizing Patient-Reported and Radiographic Outcomes and Evaluating the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Biosplice Therapeutics, Inc.
- Target Recruit Count
- 513
- Registration Number
- NCT03928184
- Locations
- ๐บ๐ธ
Research Site #1, Winter Park, Florida, United States
๐บ๐ธResearch Site 2, New York, New York, United States
๐บ๐ธResearch Site, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.